IKAP, Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-IKAP, antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityIKAP,
Clonepolyclonal
Host Speciesn/a
Reactive Specieshuman
Isotypen/a
Formatunconjugated
Size0.1 mg
Concentrationn/a
ApplicationsWestern Blot (WB)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThe transcription factor NF-kappa B coordinates the activation of numerous genes in response to pathogens and pro-inflammatory cytokines, and is, therefore, vital in the development of acute and chronic inflammatory diseases. NF-kappa B is activated by cytokine-activated IKB kinases (IKKs); IKK-alpha and IKK-beta isozymes are found in large complexes. Theses large, interleukin-1-inducible IKK complexes have been found to contain a new protein, termed IKK-complex-associated protein (IKAP), which can bind NIK and IKKs and assemble them into an active kinase complex. IKAP is a scaffold protein and a regulator for 3 different kinases involved in pro-inflammatory cytokine signaling.
ImmunogenImmunogen: C terminus of IKAP
Other Names[IkappaB kinase complex associated protein; Elongator complex protein 1; elongator complex protein 1; inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein; IkappaB kinase complex-associated protein; IKK complex-associated protein; p150], [IKBKAP; IKBKAP; FD; DYS; ELP1; IKAP; IKI3; TOT1; ELP1; IKAP; ELP1; IKK complex-associated protein]
Gene, Accession #[IKAP], Gene ID: 8518, NCBI: AAC64258.1
Catalog #MBS555267
Price$350
Order / More InfoIKAP, Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.